Ascendis Pharma A/S

Ascendis Pharma A/S announced its inclusion in several prominent Russell U.S. Indexes, effective June 26, 2026. The company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index, and the Russell Midcap® Index. This inclusion is part of the 2026 Russell U.S. Indexes semi-annual reconstitution and is expected to increase the company's visibility among institutional investors.

Ascendis Pharma A/S announced it will present new clinical data from its achondroplasia programs at ICCBH 2026. This includes Week 104 data from the pivotal ApproaCH Trial for TransCon CNP, showing improvements in lower-extremity alignment. Additionally, Week 52 radiographic and anthropometric data from the COACH Trial for combination therapy with TransCon CNP and TransCon hGH will be presented.

Ascendis Pharma A/S announced the completion of the previously disclosed sale of its Rare Pediatric Disease Priority Review Voucher (PRV). The company received $187.5 million in cash from an undisclosed buyer, prior to transaction-related expenses. This PRV was granted by the U.S. Food and Drug Administration in February 2026, following the approval of YUVIWEL (navepegritide).

Ascendis Pharma announced positive Week 182 data from its completed Phase 3 PaTHway Trial for TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism. The long-term treatment demonstrated sustained efficacy and safety over three and a half years, replicating endogenous PTH actions across target organ systems. Patients showed improved quality of life, normalized and stable urine calcium, serum calcium, serum phosphate, and bone mineral density, while achieving independence from conventional therapy. The treatment was generally well-tolerated with no new safety signals.

Ascendis Pharma announced positive Week 182 data from its completed Phase 3 PaTHway Trial for TransCon PTH in adults with hypoparathyroidism. The long-term treatment demonstrated sustained efficacy and safety over three and a half years, with 86% of patients achieving the multi-component endpoint and 89% completing the trial. TransCon PTH replicated endogenous PTH actions, improving quality of life, normalizing key biochemistries, and enhancing kidney function while enabling independence from conventional therapy.

Ascendis Pharma announced positive 5-year (Week 266) data from its Phase 2 PaTH Forward Trial for TransCon PTH (palopegteriparatide) in adults with hypoparathyroidism. The trial demonstrated sustained efficacy and safety, replicating endogenous PTH actions with beneficial impacts on kidney, small intestine, CNS, and bone. Patients showed significant improvements in serum calcium, kidney function, bone mineral density, and quality of life, while achieving independence from conventional active vitamin D and calcium therapy. The treatment was generally well-tolerated with no new safety signals.

Ascendis Pharma A/S announced the grant of an aggregate of 27,030 warrants to certain employees on June 9, 2026. Each warrant allows the holder to subscribe for one ordinary share at an exercise price of US $213.23, which was the closing price on the grant date. The warrants have a vesting schedule, with 25% vesting after one year and the remainder vesting monthly thereafter, contingent on continued service. Following this grant, 1,553,563 shares remain available for future warrant grants under the company's Articles of Association.

Ascendis Pharma A/S announced it will share the latest data from its Endocrinology Rare Disease programs at ENDO 2026, the annual meeting of the Endocrine Society. The presentations will include two oral presentations and three posters covering hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency. The company aims to showcase the long-term safety and efficacy of TransCon PTH and the long-term benefits of TransCon CNP alone and in combination with TransCon hGH.

Ascendis Pharma A/S announced that its board of directors granted an aggregate of 31,250 warrants to certain employees on May 12, 2026. Each warrant allows the holder to subscribe for one ordinary share at an exercise price of US $237.65, which was the closing price on the grant date. The warrants will vest over time, with 25% vesting on the one-year anniversary and the remaining 75% vesting monthly thereafter, contingent on continued service. Following this grant, 1,580,593 shares remain available for future warrant grants.

Ascendis Pharma reported a significant financial turnaround in Q1 2026, driven by the U.S. FDA Accelerated Approval of YUVIWEL® (navepegritide) and the recognition of substantial deferred tax assets. The company posted a net profit of €629.3 million, reversing a prior-year loss, with revenue more than doubling to €246.6 million. Additionally, Ascendis Pharma initiated a $120 million share repurchase program, buying back $60.0 million in shares during the quarter.